©2024 Stanford Medicine
Memantine Augmentation in Obsessive-Compulsive Disorder
Not Recruiting
Trial ID: NCT00264238
Purpose
The purpose of this study is to determine whether memantine is safe and effective when used
as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).
Official Title
An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder
Stanford Investigator(s)
John Barry, MD
Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology - Adult) and, by courtesy, of Neurology
Elias Aboujaoude, MD, MA
Clinical Professor, Psychiatry and Behavioral Sciences
Eligibility
Inclusion Criteria:
- at least 18 years of age
- suffering from OCD
- Y-BOCS score of 18 or greater
- taking a therapeutic dose of an anti-OCD medication specified in the protocol
Exclusion Criteria:
- diagnosed with a mental disorder other than OCD
- taking tiagabine or pregabalin
- having had a previous trial of memantine
- receiving therapy for OCD
- substance abuse in the last 6 months
- personality disorders sufficiently severe to interfere with study participation
Intervention(s):
drug: Memantine
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Nona Gamel
6507238601